Nuvation Bio Inc.
NUVB · XNYSCIK 1811063fmd_0MC4E61BNQPTYX23Z7TVTFT01SManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 8 | 63 |
| Cost of revenue | – | – | – | 0 | 7 | – |
| Gross profit | – | – | – | 0 | 1 | – |
| Research and development | 33 | 69 | 88 | 71 | 99 | 115 |
| Selling, general and administrative | – | – | – | 29 | 69 | 152 |
| Total operating expenses | 44 | 93 | 120 | 100 | 601 | 276 |
| Operating income | (44) | (93) | (120) | (100) | (593) | (213) |
| Interest expense | – | – | – | 0 | 0 | 14 |
| Other non-operating income (expense) | 2 | 6 | 16 | 24 | 25 | 8 |
| Income before taxes | (42) | (87) | (104) | (76) | (568) | (205) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (42) | (87) | (104) | (76) | (568) | (205) |
| Net income | (42) | (87) | (104) | (76) | (568) | (205) |